Severe COVID-19 Uncommon in Children, but More Likely with Pre-Existing Conditions
Pre-existing medical conditions as well as “medical complexity” increase risk for severe COVID-19 illness and hospitalization in children.
Pre-existing medical conditions as well as “medical complexity” increase risk for severe COVID-19 illness and hospitalization in children.
There is value in leveraging the contributions of nurses, laboratorians, and informaticists in antimicrobial stewardship.
Latest discoveries around HpaA’s implications for immune response and disease progression.
The assay, the cobas Malaria test, is manufactured by Roche, and will be available in the United States at the end of Q2 2024.
The long-term benefits of antimicrobial use and resistance (AUR) reporting is about improving patient care and combating resistance.
Insights on Sofosbuvir levels in pregnant women.
A new strategy for universal infant immunization in the 2023-2024 RSV season faces implementation and medication access barriers.
Here is a review of an opportunistic treatment approach to HCV infection in this patient population in a European study and some of the potential…
The evolution of treatment for hepatitis C virus during the past 15 years has been astounding, and we now are able to talk about how…
The authorization was given to Invivyd’s pemivibart (Pemgarda), and it is indicated for adults and adolescents with moderate-to-severe immune compromised conditions.
This week learn more about CDC’s strategies to reduce waterborne diseases; the US change to a trivalent influenza vaccine; new data for Merck’s pneumococcal vaccine;…